Clinical trials: Aripiprazole, completed
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2_3Y (NCT02526030)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Bipolar Disorder
Aripiprazole in Patients With Acute Mania
The purpose of this trial is to test the safety \& efficacy of aripiprazole in patients with Bipolar Mania for a period of at least 12 weeks.
- Trial name
- NCT00095511
- Testing
- aripiprazole
- Where
- 38 sites in United States
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or…
- Trial name
- NeSSy (NCT01164059)
- Testing
- Olanzapine, Flupentixol, Quetiapine
- Where
- 18 sites in Germany
- Volunteers
- 149 people
- Sponsor
- University of Bremen
Schizophrenia
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.
- Trial name
- NCT01323205
- Testing
- JNJ-40411813, Antipsychotic medication
- Where
- 20 sites in Austria, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Broad Effectiveness: Study With Aripiprazole
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
- Trial name
- NCT00036361
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Bipolar I Disorder
Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
This will be a randomized, double-blind, placebo-controlled trial to assess the time to recurrence of any mood episode in subjects with bipolar I disorder who have maintained stability on aripiprazole IM depot for at least 8…
- Trial name
- NCT01567527
- Testing
- Intramuscular (IM) Depot Aripiprazole
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 731 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophrenia Relapse
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
This prospective longitudinal cohort study will follow patients with schizophrenia who are treated with second generation long-acting injectable antipsychotic medications (LAIs) for 48 weeks to determine the risk of psychotic…
- Trial name
- NCT05473741
- Testing
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
The Effects of Aripiprazole on Patients With Metabolic Syndrome
The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- NCT00224822
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- New Mexico VA Healthcare System
Trichotillomania
Trial of Aripiprazole in Trichotillomania
No medication has been reliably shown to benefit those suffering from trichotillomania (compulsive hair pulling). The current study proposes to evaluate the effectiveness of the medication aripiprazole for treatment of…
- Trial name
- NCT00947154
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Diabetes
Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics
Antipsychotic medicines used to treat mental illnesses have been associated with effects on blood sugar control. Laboratory studies have shown that certain medications in particular may alter how insulin works.
- Trial name
- NCT01411930
- Testing
- Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Methamphetamine Dependence
A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e.
- Trial name
- NCT01822730
- Testing
- paliperidone, Risperidone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Wei Hao
Psychosis, Schizophrenia
Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning
The main objective is to investigate if the brain activation signature of a typical antipsychotic agent is dissociable from a newer drug with a pharmacological profile that differs from both typical and atypical antipsychotics…
- Trial name
- Arip_200901 (NCT01161277)
- Testing
- Aripiprazole, Haloperidol
- Where
- Norway
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Bipolar Disorder
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
The purpose of this clinical research study is to learn if outpatients with bipolar mania who are partially nonresponsive to lithium or valproate monotherapy can achieve stable symptoms on a combination treatment of aripiprazole…
- Trial name
- NCT00261443
- Testing
- Lithium or Valproate with Aripiprazole
- Where
- 83 sites in United States, Brazil and 7 more
- Volunteers
- 1,270 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
The primary objective of this trial is to evaluate the clinical efficacy and safety of aripiprazole in comparison to placebo in patients with Bipolar I Disorder experiencing a manic or mixed episode.
- Trial name
- NCT00606281
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 258 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.